Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)

Aric J Storck, Kevin B Laupland, Ronald R Read, Manuel W Mah, John M Gill, Deborah Nevett, Thomas J Louie, Aric J Storck, Kevin B Laupland, Ronald R Read, Manuel W Mah, John M Gill, Deborah Nevett, Thomas J Louie

Abstract

Background: Past clinical trials of antimicrobial treatment in soft tissue infections have focused on non-standardized clinical and physiological outcome variables, and have not considered the subjective experience of patients. The objective of this study was to develop a health-related quality of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI) for future use in clinical trials.

Methods: The design of this study followed published guidelines and included item generation, item reduction, and questionnaire preparation. Study subjects were consenting English-speaking adults with acute ESTI requiring prescription of at least two days of outpatient intravenous antibiotic therapy.

Results: A list of 49 items that adversely impact the quality of life of patients with ESTI was generated by literature review, informal health professional feedback, and semi-structured interviews with twenty patients. A listing of these items was then administered to 95 patients to determine their relative importance on quality of life. A questionnaire was prepared that included the twenty most important items with a 5-point Likert scale response. Questionnaire domains included physical symptoms, problems performing their activities of daily living, impairment of their emotional functioning, and difficulties in their social interactions as related to their ESTI. The final questionnaire was pre-tested on a further ten patients and was named the ESTI-Score.

Conclusion: The ESTI-Score is a novel instrument designed to quantify the impact of ESTI on quality of life. Future study is required to determine its validity and responsiveness before use as an outcome measure in clinical trials.

Figures

Figure 1
Figure 1
Distribution of ESTI-Scores calculated post hoc among 95 patients included in the item reduction phase.

References

    1. Gottlieb T, Atkins BL, Shaw DR. 7: Soft tissue, bone and joint infections. Med J Aust. 2002;176:609–615.
    1. Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002;66:119–124.
    1. Sharpe JN, Shively EH, Polk HCJ. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189:425–428. doi: 10.1016/j.amjsurg.2005.01.011.
    1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.
    1. Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ. Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. Jama. 1997;277:1232–1237. doi: 10.1001/jama.277.15.1232.
    1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.
    1. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77–83. doi: 10.1111/j.1365-2222.1991.tb00807.x.
    1. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS) J Clin Endocrinol Metab. 1998;83:1976–1987. doi: 10.1210/jc.83.6.1976.
    1. Flemons WW, Reimer MA. Development of a disease-specific health-related quality of life questionnaire for sleep apnea. Am J Respir Crit Care Med. 1998;158:494–503.
    1. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707–713. doi: 10.1111/1523-1747.ep12365600.
    1. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37:41–50. doi: 10.1016/S0190-9622(97)70210-X.
    1. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Cmaj. 1986;134:889–895.
    1. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis. 1985;38:27–36. doi: 10.1016/0021-9681(85)90005-0.
    1. Laupland KB, Gill MJ, Schenk L, Goodwin D, Davies HD. Outpatient parenteral antibiotic therapy: evolution of the Calgary adult home parenteral therapy program. Clin Invest Med. 2002;25:185–190.
    1. Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005;6:269–282. doi: 10.1089/sur.2005.6.269.
    1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681. doi: 10.1086/420818.
    1. Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther. 2002;24:59–72. doi: 10.1016/S0149-2918(02)85005-6.
    1. Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, McAdams A, Woods GL, Ceesay TP, Gesser R. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460–1468. doi: 10.1086/340348.
    1. Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, Brown MJ. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45:2358–2362. doi: 10.1128/AAC.45.8.2358-2362.2001.
    1. Wasilewski MM, Wilson MG, Sides GD, Stotka JL. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother. 2000;46:255–262. doi: 10.1093/jac/46.2.255.
    1. Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002;24:1134–1147. doi: 10.1016/S0149-2918(02)80024-8.
    1. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683–693.
    1. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669–1674. doi: 10.1001/archinte.164.15.1669.
    1. Leppard BJ, Seal DV, Colman G, Hallas G. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol. 1985;112:559–567.
    1. Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004;350:904–912. doi: 10.1056/NEJMcp031807.
    1. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med. 1996;14:547–551. doi: 10.1016/S0736-4679(96)00126-6.
    1. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract. 1985;35:185–188.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner